Showcases Stock ranks Forex

Biogen Inc (BIIB)
280.21  -1.5 (-0.53%) 05-14 16:00
Open: 277.17 Pre. Close: 278.39
High: 280.6902 Low: 273.09
Volume: 954,931 Market Cap: 42,187M
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 281.103 - 282.52 282.52 - 283.685
Low: 269.84 - 271.328 271.328 - 272.552
Close: 277.988 - 280.365 280.365 - 282.32
Stock Technical Analysis
Target: Six months: 330.73
One year: 386.29
Support: Support1: 267.01
Support2: 257.03
Resistance: Resistance1: 283.16
Resistance2: 330.73
Pivot: 272.74
Moving Averages: MA(5): 277.99
MA(20): 271.24
MA(100): 268.14
MA(250): 271.56
MACD: MACD(12,26): 2.53
Signal(12,26,9): 1.28
%K %D: %K(14,3): 83.36
%D(3): 82.35
RSI: RSI(14): 59.26
52-Week: High: 363.92
Low: 223.25
Change(%): -11.3
Average Vol(K): 3-Month: 109879
10-Days: 93599
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.

BIIB has closed below upper band by 10.8%. Bollinger Bands are 13.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 14 May 2021
Do Traders Think Biogen Inc (BIIB) Can Keep Climbing Friday? - InvestorsObserver

Fri, 14 May 2021
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate - Yahoo Finance

Fri, 14 May 2021
Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study - Benzinga

Wed, 12 May 2021
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders - Yahoo Finance

Mon, 03 May 2021
Was The Smart Money Right About Biogen Inc. (BIIB)? - Yahoo Finance

Wed, 28 Apr 2021
Is Biogen Inc (BIIB) Stock Over or Undervalued? - InvestorsObserver

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 150.56
Shares Float (M) 149.51
% Held by Insiders 0.63
% Held by Institutions 87.78
Shares Short (K) 3240
Shares Short Prior Month (K) 3970
Stock Financials
EPS 19.290
Book Value (p.s.) 70.930
Profit Margin 23.89
Operating Margin 29.40
Return on Assets (ttm) 9.3
Return on Equity (ttm) 26.5
Qtrly Rev. Growth -23.8
Gross Profit (p.s.) 77.311
Sales Per Share 83.688
EBITDA (p.s.) 27.829
Qtrly Earnings Growth -70.70
Operating Cash Flow (M) 3530.00
Levered Free Cash Flow (M) 2470.00
Stock Valuation
PE Ratio 14.53
PEG Ratio
Price to Book value 3.95
Price to Sales 3.35
Price to Cash Flow 11.95
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator